Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial. (linkinghub.elsevier.com)

Authors: Baden LR … Zimmerman KO Journal: Lancet Infectious Diseases Published: 2026-08-31 DOI: https://doi.org/10.1016/S1473-3099(26)00406-8